Technical Analysis for AUPH - Aurinia Pharmaceuticals Inc

Grade Last Price % Change Price Change
F 5.09 -1.55% -0.08
AUPH closed down 1.55 percent on Monday, March 18, 2024, on 48 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
180 Bearish Setup Bearish Swing Setup 0.00%
Oversold Stochastic Weakness 0.00%
Jack-in-the-Box Bearish Bearish Swing Setup -1.55%
Pocket Pivot Bullish Swing Setup -1.55%
Narrow Range Bar Range Contraction -1.55%
Inside Day Range Contraction -1.55%
Oversold Stochastic Weakness -1.55%
New 52 Week Closing Low Bearish 0.00%
Expansion Breakdown Bearish Swing Setup 0.00%
New 52 Week Low Weakness 0.00%

   Recent Intraday Alerts

Alert Time
Rose Above Previous Day's High about 16 hours ago
60 Minute Opening Range Breakout about 16 hours ago
Down 2 % about 19 hours ago
Down 1% about 19 hours ago
3x Volume Pace 4 days ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, is engaged in the development of a therapeutic drug to treat autoimmune diseases in Canada. The company's lead drug includes Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has a development and license agreement with 3SBio Inc. for the clinical development, registration, and commercialization of voclosporin in China; and licensing and collaboration agreement with Vifor Pharma for the treatment of lupus and various proteinuric nephrology indications. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Life Sciences Drugs Clinical Development Autoimmune Disease Peptides Lupus Nephrology Immunosuppressants Lupus Nephritis Nephritis

Is AUPH a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 12.421
52 Week Low 4.98
Average Volume 2,618,047
200-Day Moving Average 8.56
50-Day Moving Average 6.96
20-Day Moving Average 5.58
10-Day Moving Average 5.32
Average True Range 0.29
RSI (14) 26.47
ADX 45.39
+DI 9.09
-DI 33.66
Chandelier Exit (Long, 3 ATRs) 5.34
Chandelier Exit (Short, 3 ATRs) 5.84
Upper Bollinger Bands 6.19
Lower Bollinger Band 4.97
Percent B (%b) 0.1
BandWidth 21.85
MACD Line -0.54
MACD Signal Line -0.56
MACD Histogram 0.0234
Fundamentals Value
Market Cap 730.96 Million
Num Shares 144 Million
EPS -0.54
Price-to-Earnings (P/E) Ratio -9.43
Price-to-Sales 7.49
Price-to-Book 3.04
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.33
Resistance 3 (R3) 5.35 5.28 5.29
Resistance 2 (R2) 5.28 5.22 5.28 5.28
Resistance 1 (R1) 5.19 5.18 5.16 5.17 5.26
Pivot Point 5.12 5.12 5.11 5.12 5.12
Support 1 (S1) 5.03 5.06 5.00 5.01 4.92
Support 2 (S2) 4.96 5.02 4.96 4.90
Support 3 (S3) 4.87 4.96 4.89
Support 4 (S4) 4.85